A ctivation of cells of the innate immune system, including professional APCs, with vaccine adjuvants strongly influences the efficacy of adaptive immunity induced by vaccination (1) . Furthermore, cells of the innate immune system are also the first line of antitumor defense capable of early recognition and killing of autologous cells with aberrant immunophenotypes. NK cells and macrophages (M) 3 are both involved in anti-tumor immune defense (2) (3) (4) .
An array of stimulatory receptors on naive NK cells allows for recognition of cancer cells with altered surface expression of MHC class I Ags (MHC-I) or MHC-I-like structures, such as H60, MULT1, and Rae-1 proteins in mice, and MHC-I chain-related proteins (MICA and MICB) and UL16-binding proteins (ULPB) in humans, which results in NK cell activation (5) (6) (7) (8) (9) (10) . This effect frequently requires mutual coligation of multiple activating receptors and adhesion molecules on NK cells (11, 12) and can further be augmented by stimulation of NK cells via cytokines or TLRs (13) . Notably, activation of secretory and cytolytic functions may require different patterns of NK cell costimulation (11, 13) . Interactions involved in cancer cell recognition by naive M are less well characterized. Several studies demonstrated roles for MHC-I and MHC-I-like molecules in regulation of M activation (10, 14 -17) . The CD11b-CD18 complex (also known as LFA-1) on M has also been shown to regulate M-mediated tumor cell cytolysis by facilitating anchoring of the ICAM ϩ tumor cell targets to activated M (18, 19) . M also express CD40 on their membranes and therefore could be stimulated via CD40 ligation. Indeed, we have recently reported that in vitro and in vivo stimulation of M with agonistic anti-CD40 mAb (anti-CD40) results in M activation that could be synergistically amplified via TLR4 by bacterial LPS or via TLR9 by class B CpG-containing oligodeoxynucleotides (20, 21) . These anti-CD40-stimulated M could secrete NO, TNF-␣, IL-12, and IFN-␥ and mediate antitumor effects in vitro and in vivo against CD40-negative tumors (20, 21) .
In several experiments pertaining to our previous studies, we observed that culturing naive M in vitro with L5178Y T cell lymphoma cells in the presence of low concentrations of LPS resulted in secretion of NO and induced tumor cytostasis. Notably, M and L5178Y cells cultured separately did not secrete any detectable NO in the presence of LPS. This led to the hypothesis that tumor cells can sensitize naive M via TLR4. In this study, we investigated the mechanisms of this L5178Y cell-mediated priming of naive M and found that it required direct L5178Y cell-M interaction and involved simultaneous ligation of CD40, NKG2D, and CD18 on the M surface, with the CD40-CD154 interaction playing the most important role. This cross-talk also led to reciprocal alterations of the immunophenotype of both M and L5178Y cells and resulted in inhibition of L5178Y cell proliferation in vitro. The priming of M with L5178Y cells was also demonstrated in vivo, suggesting that M activation can be a mechanism of immunological lymphoma surveillance.
Materials and Methods

Mice
Six-to 10-wk-old C57BL/6 mice (Harlan Sprague Dawley, The Jackson Laboratory, and Taconic Farms), DBA/2, BALB/c, A/J mice (all from Taconic Farms), and CD40 Ϫ/Ϫ mice (strain B6.129P2-CD40tm1Kik/J; The Jackson Laboratory) were housed, cared for, and used in accordance with the Guide for Care and Use of Laboratory Animals (National Institutes of Health publication 86-23, National Institutes of Health, Bethesda, MD, 1985) .
Tumor cell lines
Mouse L5178Y T cell lymphoma (DBA/2 origin), EL4 T cell lymphoma (C57BL/6), YAC-1 thymoma (A/Sn), A20 B cell lymphoma (BALB/c), B16 melanoma (C57BL/6), and NIH-3T3 fibroblast (BALB/c) cell lines were grown in RPMI 1640 complete cell culture medium supplemented with 10% FBS (Sigma-Aldrich), 2 mM L-glutamine, 100 U/ml penicillin/ streptomycin, and 0.5 M 2-ME (Invitrogen Life Technologies) at 37°C in a humidified 5% CO 2 atmosphere. Human Jurkat T cell lymphoma, Daudi B cell lymphoma, and M21 melanoma cell lines were grown in RPMI 1640 
FIGURE 2. L5178Y cells induce dose-dependent priming of naive M
to LPS but not CpG. Adherent C57BL/6 M were cultured for 48 h alone or with 2.5 ϫ 10 4 /well of L5178Y lymphoma cells or autologous splenocytes (A and B) or various numbers of L1578Y cells (as shown in the legend box) in a separate experiment (E and F), in medium with or without LPS (10 ng/ml, as well as 0.1 and 1000 ng/ml in E and F) or CpG (5 g/ml). Alternatively (C and D), C57BL/6 M were cultured with 2.5 ϫ 10 4 /well of L5178Y lymphoma cells or splenocytes from DBA/2 mice for 24 h, followed by thorough removal of L5178Y cells and splenocytes and placement of 2. complete cell culture medium, as formulated above, but without 2-ME. Mouse fibroblast L cell line (ATCC CRL-2648) and CD40L or control CD32 (FcR)-transfected L cells (CD40L-L and CD32-L, respectively), provided by Dr. E. Ranheim (University of Wisconsin Department of Pathology and Laboratory Medicine) were cultured in RPMI 1640 complete medium with G418 (400 g/ml). In separate experiments, we used paraformaldehyde-fixed (PF) L5178Y cells (PF-L5178Y) prepared by exposing L5178Y cells to 2% paraformaldehyde in PBS on ice for 1 h, followed by five separate cell wash cycles with complete cell culture medium. The fixed cells were kept in ice-cold medium for 24 h to allow for complete elimination of any contaminating paraformaldehyde. Cell death was confirmed microscopically by staining with 1% eosin.
Splenocyte preparation
Splenocytes were prepared from whole spleens pooled from three to four C57BL/6 or DBA/2 mice by processing the spleens to a single-cell suspension, followed by lysis of erythrocytes by hypotonic shock.
In vitro M-mediated tumor cell proliferation inhibition
Peritoneal cells (PC) were obtained from naive mice by peritoneal cavity lavage. Total PC were seeded in 96-microwell flat-bottom cell culture clusters (3 ϫ 10 6 viable large leukocytes/ml, 0.1 ml/well, unless otherwise indicated). Ninety minutes later, nonadherent cells were removed from the culture by repeated pipetting. This protocol yields a relatively pure population of mature M, based on 98% expression of F4/80 on CD11b ϩ cells. The resultant adherent M were thereafter incubated with tumor cells (5 ϫ 10 5 /ml, 0.05 ml/well, unless otherwise indicated) or splenocytes for 24 -48 h in medium with or without 10 ng/ml LPS from Salmonella enteritidis (Sigma-Aldrich) or 5 g/ml CpG1826 (Coley Pharmaceuticals) in the final volume of 0.2 ml.
In some experiments, M were activated with recombinant mouse IFN-␥ (Roche) or agonistic anti-CD40 mAb (20, 21) . The FGK 45.5 hybridoma producing anti-CD40 was a gift from Dr. F. Melchers (Basel Institute for Immunology, Basel, Switzerland). anti-CD40 was obtained from ascites of nude mice injected with the hybridoma cells and enriched for IgG by ammonium sulfate precipitation.
In selected experiments, 10 g/ml functional grade blocking mAbs to NKG2D (191004; R&D Systems), CD154 (MR1), CD18 (M18/2), MHC-I (34-1-2S reacts with both H-2K d and H-2D d ; all from eBioscience), alone or in various combinations, were added into M cultures at the initiation of the experiment, but 30 min before tumor cells and LPS were added to the cultures. In the setting where anti-CD154 mAb was used, L5178Y cells were additionally precoated with 10 g/ml anti-CD154 mAb or control IgG on ice for 30 min and added to M cultures without additional washing.
To measure cell proliferation, the cells were pulsed with 
Transwell (TW) experiments
In separate experiments, we used the TW system (Costar 3460, 12-macrowell polystyrene plates with 12 mm, 0.4-m pore size polyester membrane TW chambers). Total PC at a concentration of 3 ϫ 10 6 large leukocytes/ml (1.0 ml/well) were plated into wells for 90 min before nonadherent cells were removed, and 1.45 ml of complete cell culture medium was replaced. L5178Y cells (5 ϫ 10 5 /ml, 0.5 ml/well) were added either into the wells or into the TW chamber. Under certain experimental conditions, L5178Y cells were added both in the wells and in the TW chamber. Finally, LPS (0.4 g/ml, 0.05 ml/well) was added in the well to achieve the final concentration of 10 ng/ml in 2.0 ml. After 24 h of coculture, the TW chambers were removed from the wells and placed into 15-ml centrifuge conical tubes. To harvest L5178Y cells from the TW chamber, the polyester membrane was delicately perforated by the tip of a 1-ml pipette, and L5178Y cells were washed off by repeated pipetting of cell culture medium through the TW chamber. In the same wells, nonadherent L5178Y cells, cultured together with adherent M, were harvested from the bottom of the macrowells by gentle pipetting and repeated aspiration of the cell culture supernatants. This technique yielded Ͼ95% of total L5178 cells cultured in the well, with Ͻ2% of contaminating M detached from plastic by pipetting. Finally, the harvested L5178Y cells (from the TW chambers or the bottom of the wells) were spun down, the pellet was resuspended in 0.3 ml of the cell culture medium, and the cells were reseeded in 96-microwell round-bottom cell culture clusters in triplicate, 0.1 ml/well. Inhibition of L5178Y cell proliferation was measured with [ 3 H]TdR as described above.
NO detection
M were cultured with tumor cells as described above. At different time points, the cell culture supernatants were collected without disturbing the cell monolayers. In experiments involving the TW system, the supernatants were taken from both the well and the TW chamber. Nitrite accumulation in the cell culture supernatants was determined by using the Griess reagent (Sigma-Aldrich) as previously described (20) .
Tumor cell medium conditioning
L5178Y cells (5 ϫ 10 5 cells/ml, 20 ml) were cultured in complete cell culture medium, with or without 10 ng/ml LPS, at 37°C in a humidified 5% CO 2 atmosphere. At 24 h, cell cultures were harvested and cells were pelleted by centrifugation at 453 ϫ g for 20 min. Cell culture supernatants were collected and centrifuged at 3220 ϫ g for 60 min, and the resultant supernatants were subsequently used in in vitro experiments.
Tumor cell testing for Mycoplasma spp. contamination L5178Y, YAC-1, and B16 tumor cell lines were tested for contamination with Mycoplasma spp. as described elsewhere (22 
In vivo L5178Y lymphoma-mediated M priming
DBA/2 mice (n ϭ 3) were injected i.p. with 5 ϫ 10 5 L5178Y cells in 1 ml of PBS. The control group of mice was injected with 1 ml of PBS without tumor cells. Twenty-four hours later, animals were injected i.v. with 20 ng of LPS in 0.2 ml of PBS or with 0.2 ml of PBS (control). At 48 h of the experiment, animals were euthanized and then PC were collected by lavage and seeded in 6-well plates in complete RPMI 1640 medium to allow for purification of M by adhesion (20) .
Flow cytometry analysis
Adhesion-purified peritoneal M from C57BL/6 mice were harvested as described above and resuspended in ice-cold PBS plus 2% FCS. M (1 ϫ 10 5 /sample) were labeled with FITC-conjugated anti-CD11 (M1/ 70), allophycocyanin-conjugated anti-F4/80 (BM8), and PE-conjugated 
In vivo tumoristasis assay
CFSE-labeled L5178Y cells (5 ϫ 10 5 /ml) were injected i.p. into DBA/2 mice (n ϭ 3/group). Twenty-four hours after CFSE ϩ L5178Y cell implantation, the mice were treated i.v. with 0.2 ml of PBS with or without 20 ng of LPS. After 48 h, mice were euthanized, resident PC plus lymphoma cells were collected from each mouse of the group and pooled, and F4/80
Ϫ CFSE ϩ L5178Y were tested by flow cytometry for CFSE fluorescence. In parallel, CFSE ϩ L5178Y cells (5 ϫ 10 5 /ml, 0.05 ml/well) were cultured in vitro in triplicates with naive DBA/2 M as described above in an in vitro M-mediated tumor cell proliferation inhibition assay. After 48 h, cell cultures were collected by pipetting and pooled into one analysis sample for each experimental group, and F4/80
Ϫ CFSE ϩ L5178Y were tested by flow cytometry for CFSE fluorescence. As a proliferation suppression control, L5178Y cells were ␥-irradiated by a 60 Co ␥ source.
Statistical analysis
A two-tailed Student's t test was used to determine the significance of differences between experimental and relevant control values within one experiment. Statistical analysis of the inhibition of tumor cell proliferation under different experimental conditions was performed on original [ 3 H]TdR incorporation values, which were also used to calculate the percentage of inhibition. coculture, we tested the cell cultures for NO concentration in the supernatant (Fig. 1B) , as well as inhibition of [ 3 H]TdR incorporation into the tumor cells (Fig. 1C) . The results of this experiment show that only L5178Y cells, but not any of the other cells tested, were able to prime M to LPS, as measured by production of NO and antilymphoma effects in vitro. This priming effect of L5178Y cells on M was similar using PC M harvested from syngeneic DBA/2 and allogeneic C57BL/6 (but not from BALB/c or A/J) mouse strains obtained from various vendors as summarized in Table I . In contrast, EL4 cells primed neither allogeneic (DBA/2) nor syngeneic (C57BL/6) M (Fig. 1, B and C, and data not shown).
Results
L5178Y lymphoma cells but not other tumor cell lines prime M to LPS
L5178Y lymphoma cells but not normal splenocytes prime naive M to LPS but not CpG
We tested whether culturing naive M with L5178Y lymphoma cells would result in M priming to CpG as well as LPS, as we have previously reported that both LPS and CpG could trigger CD40 ligation-primed M (21). M from C57BL/6 mice were cultured for 48 h with either L5178Y cells or splenocytes from the same donor mice (to further test whether the observed priming effect is specific for L5178Y tumor cells) in culture medium with or without LPS or CpG. As shown in Fig. 2A , naive M cultured in medium failed to respond to LPS or CpG as measured by NO production. In contrast, M were found to secrete a substantial amount of NO when cultured with L5178Y cells but not with normal splenocytes and only in response to LPS but not CpG. This pattern of M secretory activity induced by coculture with L5178Y cells directly correlated with inhibition of L5178Y cell proliferation (Fig. 2B) , whereas the antiproliferative effect of M primed with splenocytes was substantially weaker and not reproducible in every experiment.
To test whether L5178Y cell-mediated priming followed by LPS stimulation would enable M to be cytotoxic to tumor cells other than L5178Y, we primed C57BL/6 M with L5178Y cells or splenocytes from DBA/2 mice (so that lymphoma cells and splenocytes would be of the same H-2 d haplotype) for 24 h in complete medium. L5178Y cells or splenocytes were then removed and replaced by freshly prepared L5178Y cells or B16 cells for another 24 h period with or without LPS (Fig. 2, C and  D) . As in the previous experiment (Fig. 2, A and B) , L5178Y cells but not splenocytes from naive donors could prime M to respond to LPS, resulting in cytotoxicity not only against the priming cell line (L5178Y), but also against the B16 melanoma cell line, which does not possess the priming ability (Fig. 1, B  and C) .
NO production by M cultured with L5178Y cells in the presence of LPS correlated with the number of L5178Y cells present in culture (Fig. 2E) . The greater the number of L5178Y cells in the culture, the higher the concentration of NO detected in the supernatants when using 10 ng/ml LPS. Increasing the amount of LPS in the cell culture medium to 1000 ng/ml induced NO secretion even in the absence of L5178Y cells; the addition of L5178Y cells did further boost NO secretion, but did not show cell-dose sensitivity in the range tested. Notably, L5178Y cells themselves did not produce any NO in response to LPS or CpG (data not shown), which suggests that this NO was produced by activated M. The pattern of M-mediated antiproliferative effects in these same cultures (Fig. 2F ) corresponded approximately to NO production (Fig. 2E ). These results demonstrate that L5178Y cells, but not normal splenocytes, can augment the sensitivity of naive M to LPS, but not CpG, that results in in vitro NO release and antitumor effects.
Contact with L5178Y cells must precede or occur simultaneously with LPS stimulation in the course of activation of M
Next, we tested whether priming signals provided by L5178Y cells, and stimulation by LPS, need to occur in a certain sequence to activate cytotoxic M. Thus, L5178Y cells and LPS were added to M cultures either simultaneously (Fig. 3, A-C) at the beginning of the experiment, or L5178Y cells were added at the beginning of the experiment and LPS was added at 24 h (Fig. 3, D-F) , or LPS was added at the beginning of the experiment and L5178Y cells were added at 24 h in the course of the experiment (Fig. 3,  G-I) . The overall duration of the experiment was 48 h. Results of this experiment demonstrate that M exposed simultaneously to both L5178Y cells and LPS were able to secrete progressively higher amounts of NO, as measured at 24 h (Fig. 3A ) and 42 h (Fig.  3B ) of the experiment, and to inhibit L5178Y cell proliferation at the end of the experiment (Fig. 3C) . The magnitude of these effects depended upon the number of L5178Y cells present in the cultures. At the same time, M cultured with L5178Y cells added at 1 h but without LPS did not secrete any NO or inhibit L5178Y cell proliferation (the two to four columns to the left in Fig. 3, A-C) . Similarly, when M were exposed to L5178Y cells only, i.e., without LPS, for the first 24 h, they secreted only negligible amounts of NO detected at 24 h (Fig. 3D) . However, when LPS was added at 24 h to the culture of M and L5178Y cells, M rigorously responded to LPS stimulation and secreted a high amount of NO 18 h later (at 42 h of the experiment; Fig. 3E ) that was comparable to the amount of NO secreted by M simultaneously exposed to both L5178Y cells and LPS for 42 h (Fig. 3B ). These M were also able to inhibit L5178Y cell proliferation (Fig. 3F) , similar to the results shown in Fig. 2C . In contrast, when M were first stimulated with LPS for 24 h and then exposed to L5178Y cells for another 24 h, they secreted only negligible amounts of NO at both 24 h (Fig. 3G ) and 42 h (Fig. 3H) and were unable to suppress L5178Y cell proliferation (Fig. 3I) . These results indicate that the contact of M with L5178Y cells needs to precede or occur simultaneously with LPS stimulation when these two stimuli are combined to activate M.
Incubation with L5178Y tumor cells induces alteration of M immunophenotype
In addition to testing M abilities to produce NO and suppress tumor cell proliferation, we determined whether M exposure to L5178Y cells and LPS had an effect on M immunophenotype. Adherent naive M were cultured with or without L5178Y cells in the absence or presence of LPS. In our previous experiments (Fig. 3A) , we found that coculture of M with L5178Y cells and LPS for 24 h led to M activation and production of a substantial amount of NO. Therefore, after 24 h of coculture, the culture supernatants and the L5178Y cells (growing nonadherently) were removed by repeated gentle pipetting and aspiration. Following this, the adherent M were additionally washed with warm PBS and harvested by vigorous pipetting with PBS containing EDTA for flow cytometric analysis. Expression of CD40, NKG2D, TLR9, CD18, MHC class II, CD80, and CD86 Ags by M was evaluated. The results (Fig.  4A) show that culturing M with L5178Y cells plus LPS suppressed expression of CD40 (7-25% in three separate experiments) and CD18 (17-29%), but induced substantial up-regulation (44 -127%) of expression of NKG2D (Fig. 4, A and B) , CD80 (16 -23%), CD86 (101-328%), and MHC-II (201-585%) on M. The magnitude of NKG2D expression by M has remained somewhat controversial, probably because of the low amounts of NKG2D expressed on the cell surface of macrophages. 
Alterations of immunophenotype of L5178Y lymphoma cells exposed to M
Because L5178Y tumor cells in the presence of LPS altered the phenotype of M (Fig. 4) , we hypothesized that exposure to activated M may result in phenotypic changes of tumor cells. First, L5178Y, EL4, A20, B16, and NIH-3T3 mouse cell lines (cultured in medium alone) were tested by flow cytometry for expression of MHC-I (H2K), ICAM-1, ICAM-2, CD154, and H60 Ags (Fig.  5A ), which were previously shown to be involved in a cross-talk with immune effectors. The results of this experiment suggest that no two cell lines were similar in the pattern and magnitude of expression of the tested surface Ags. Only L5178Y cells were found to express detectable levels of all of the Ags at the time of analysis. Hence, the phenotype of L5178Y cells was established as
ϩ H60 ϩ . We tested whether exposure of L5178Y cells to M (with or without LPS) would result in alterations of this immunophenotype. L5178Y cells were cultured either alone, as shown in Fig. 4A , or with adherent M in medium with or without LPS. We did this analysis at 12 h rather than at 24 h (as done for M) to avoid manipulations with dead or dying L5178Y cells undergoing apoptosis. Following 12 h of coculture, L5178Y cells were harvested and the immunophenotype was evaluated (Fig. 5B) . The expression of MHC-I (H2 k ) and ICAM-1 was minimally increased following coculture with M, and the expression of H60 was slightly down-regulated with or without LPS. No regulatory effect on expression of ICAM-2 was documented. Interestingly, the expression of CD154 nearly doubled, provided that L5178Y cells were cultured with M and LPS. Notably, culture with LPS alone induced no alterations of L5178Y cell immunophenotype. Hence, crosstalk between M and L5178Y cells results in reciprocal alterations in the immunophenotype of both M (Fig. 4 ) and L5178Y cells (Fig. 5B) , and priming of M to LPS via TLR4, that ultimately leads to activation of anti-tumor M (Figs. 1, B and C, and Fig. 2) .
The cross-talk between M and L5178Y cells requires direct cell-cell contact
We determined whether direct M-tumor cell contact is required for the effects observed in the previous experiments. We used the TW in vitro system that allows for exchange of soluble secretory products, but not direct cell membrane contacts between M and L5178Y cells cultured in the same well. M were adhered to the bottom of the well and L5178Y cells were placed either together with M at the bottom of the well or in the TW chamber. In some wells, L5178Y cells were placed both on the bottom of the well and in the TW chamber. It was found that M could secrete substantial amounts of NO (Fig. 6A ) and mediate in vitro antilymphoma effects (Fig. 6B ) only when both M and L5178Y cells were cocultured in close proximity, but not when they were separated by the semipermeable membrane. When L5178Y cells were present both on the bottom of the well and in the TW chamber, the LPS-activated antiproliferative effect was mediated only toward those L5178Y cells that were cultured in proximity to M (Fig.  6B) , despite apparent equilibrium of the NO (and presumably other cytotoxic factors secreted by activated M) in both compartments of the TW system (Fig. 6A) . Only viable but not paraformaldehyde-fixed L5178Y cells triggered M activation, suggesting that either secretory activity or membrane fluidity and surface ligand rearrangements of L5178Y cells were involved in the cross-talk with M.
To clarify a possible role of L5178Y cell-secreted factors in the M-L5178Y cross-talk, we used the L5178Y cell-conditioned supernatants from these lymphoma cell cultures grown for 24 h in medium with or without LPS. As shown in Fig. 6C , only L5178Y cells but not L5178Y cell-derived secretory products resulted in M activation and NO production. Hence, these findings demonstrate that direct and active cross-talk between naive M and viable L5178Y cells is required for polarization of naive M into immune effectors with cytotoxic properties.
Priming of M by L5178Y cells involves concurrent ligation of CD40, CD18, and NKG2D
Multiple receptor-ligand interactions were previously shown to be involved in recognition of tumor cells by various immune effectors. As shown in Fig. 5A, L5178Y cells express CD154, ICAM-1 , ICAM-2, and H60, which are known to be the functional ligands to CD40, CD18, and NKG2D receptors, respectively, expressed by M (Fig. 4) . Therefore, we tested whether these receptor-ligand pairs are involved in the M-L5178Y cell cross-talk. To exclude the potential contribution of MHC-I mismatch between M and L5178Y cells, we used naive M from DBA/2 mice, which were previously found to be sensitive to the priming effect by L5178Y cells (Table I) . To investigate the roles of CD40-CD154, NKG2D-H60, and CD18-ICAM-1/2 interactions in the M-L5178Y cell cross-talk, we cultured M and L5178Y cells for 24 h in medium with or without LPS and in the presence of blocking mAbs to the receptors or ligands. These blocking mAbs were used alone or in different combinations. Isotype-matched IgGs were used as control. When a combination of blocking mAbs was tested, anti-MHC-I (specific for both H-2K
d and H-2D d ) was used both as a control for potential Ab-dependent cellular cytotoxicity via FcRs on M and as a negative control, as it would bind to both the M and the L5178Y cells, but not directly interact with the specific receptor-ligand pairs that are recognized by the blocking mAbs. When a single blocking mAb was used (anti-CD154), it was found that interference with CD40-CD154 interactions reduced NO production (Fig. 7A ) and in vitro antiproliferative effects by ϳ50% (Fig. 7B) . In contrast, blocking single interactions via CD18-ICAM-1/2 (anti-CD18) or NKG2D-H60 (anti-NKG2D) had no distinct inhibitory effect on M priming. These mAbs did not activate M, thereby ruling out that their cross-linking by FcRs had a significant agonistic effect. The three mAb combinations of anti-CD154 with either anti-CD18 or with anti-NKG2D and anti-MHC-I mAbs did not add to the effect of anti-CD154 mAb alone. However, simultaneous blocking of CD154, CD18, and NKG2D Ags on M (using the three mAb combination of anti-CD154, anti-CD18, and anti-NKG2D) led to complete abrogation of M priming and antilymphoma effects in vitro (Fig. 7) . This experiment was repeated three times with similar results.
CD40-CD40L interaction is important for M priming by tumor cells
In the next series of experiments, the role of CD40-CD40L interaction in M priming by tumor cells was further addressed. We
Ϫ CD154 Ϫ B16 cells with naive M in medium with or without LPS in the presence of agonistic anti-CD40 (Fig. 8) . In this experiment, we chose to use low (1 and 5 g/ml) concentrations of anti-CD40, which we previously found to induce no or very little M activation in vitro (20) . Fig. 8A shows that L5178Y cells, but not A20 and B16 cells, could prime M in the presence of LPS but in the absence of exogenous anti-CD40. Adding anti-CD40 at 1 g/ml to these cultures caused M activation in the presence of A20 cells but not B16 cells, nor did it further enhance the priming induced by L5178Y cells. Adding anti-CD40 at 5 g/ml did not induce priming of M by B16 cells, but increased the M-priming ability of both L5178Y and A20 cells, as shown by augmented NO production (in the presence of L5178Y cells) and tumoristasis (of both L5178Y and A20 cells). Hence, an additional signal provided by exogenous anti-CD40 was sufficient to enable M priming by CD154
Ϫ ICAM-1 ϩ ICAM-2 Ϫ H60 ϩ A20 cells, but was not enough to enable M priming by CD154 cells, consistent with the hypothesis that ligation of CD40, CD18, and NKG2D receptors is required for priming of M. Exogenous anti-CD40 also augmented M priming by CD154 ϩ ICAM-1 ϩ ICAM-2 ϩ H60 ϩ L5178Y cells, but only at the higher dose. The importance of CD40-CD40L interaction for M priming was confirmed using M from CD40 Ϫ/Ϫ mice (Fig. 8, B-E) . The priming effect of L5178Y cells and anti-CD40, used alone or in combination, on CD40 Ϫ/Ϫ M was either abrogated (Fig. 8D ) or substantially reduced (Fig. 8E) . However, CD40
Ϫ/Ϫ M were readily primed by IFN-␥, which served as a positive control demonstrating the ability of these M to become activated via other mechanisms.
To further clarify the role of CD40-CD40L interaction in priming of M by tumor cells, we used mouse L fibroblasts transfected with CD40L or CD32 (transfection control). In preliminary experiments, CD40L-L cells were confirmed to stimulate proliferation of mouse splenic CD19 ϩ B cells (data not shown). These CD40L-L and CD32-L lines also expressed ICAM-2 and H60, thereby showing phenotypic similarity with L5178Y cells (Fig.  9A) . However, in contrast to L5178Y cells, CD40L-L cells could not effectively prime M to subsequent stimulation with LPS, which was shown by a limited NO production (Fig. 9B ) and absence of cytostasis (Fig. 9C) .
However, when CD40L-L cells were mixed together with a small number of viable L5178Y cells (0.5-1 ϫ 10 4 cells/well) that would be otherwise insufficient to prime M (Figs. 1-3 ), M became activated and were found to secrete NO (Fig. 10A) . This synergistic priming effect was observed only when L5178Y cells were combined with CD40L-L but not CD32-L cells, suggesting that the interaction of CD40L on tumor cells with CD40 on M is required for the priming. Interestingly, A20 cells were also able to provide costimulation to enable CD40L-L cells, but not CD32-L cells, to prime M (Fig. 10B) . These results suggest that costimulation by L5178Y and A20 cells does not require CD154 expression in cis, as A20 cells are CD154 negative (Fig. 9A ), but might depend on the expression of ICAM-1 or soluble factors secreted by lymphoma cells.
To confirm the importance of CD40-CD40L interaction for efficient priming of M in this test model, we stimulated M from CD40 ϩ/ϩ and CD40 Ϫ/Ϫ mice with CD40L-L and L5718Y cells (1 ϫ 10 4 cells/well) alone or in combination. Similarly to the results shown in Fig. 8, B -E, the priming of M with a combination of these tumor cells was substantially reduced in CD40 Ϫ/Ϫ mice compared with CD40 ϩ/ϩ mice, as shown by decreased NO production (Fig. 10C) . Along with the findings presented above, these results demonstrate that the M priming we observed with the tumor cells tested here is a consequence of tumor cell expression of CD40L, ICAM-1, and H60. 5 /ml) were injected i.p. into DBA/2 mice (n ϭ 3/group). Twenty-four hours after tumor cell implantation, the mice were treated i.v. with 0.2 ml of PBS with or without 20 ng of LPS. After 48 h, mice were euthanized, resident PC ϩ tumor cells were collected from each mouse of the group and pooled, and F4/80
Ϫ CFSE ϩ L5178Y were tested by flow cytometry for CFSE fluorescence. In parallel, CFSE-labeled L5178Y cells (5 ϫ 10 5 /ml, 0.05 ml/well) were cultured in vitro in triplicates with naive DBA/2 M as described in Fig. 3, D-F . After 48 h, cell cultures were collected by pipetting and pooled into one analysis sample for each experimental group, and F4/ 80
Ϫ CFSE ϩ L5178Y were tested by flow cytometry for CFSE fluorescence. As a proliferation suppression control, L5178Y cells were ␥-irradiated.
Results are presented as CFSE MFI.
L5178Y cells prime mouse naive M in vivo
In the next series of experiments, we tested whether the priming of M with L5178Y lymphoma cells observed in vitro can also take place in vivo. L5178Y cells (5 ϫ 10 5 ) were implanted i.p. into naive DBA/2 mice, followed by i.v. injection of 20 ng of LPS 24 h later. This dose was used to achieve an endotoxin concentration in vivo similar to that used in our in vitro experiments (10 ng/ml): the mice used in the experiments, weighing ϳ30 g each, have a blood volume of ϳ2 ml. Three other groups of mice received L5178Y cells alone, LPS alone, or PBS (control). After 48 h, PC were harvested and M were tested for production of IL-4, IL-10, IFN-␥, TNF-␣, and IL-12p40, as well as alterations of expression of NKG2D, CD80, CD86, and MHC-II surface Ags (Fig. 11A) .
Injection of L5178Y cells alone slightly augmented production of IFN-␥ (42%) and TNF-␣ (40%), as well as significantly upregulated MHC-II (900%) by M. LPS alone augmented secretion of IFN-␥ (125%), TNF-␣ (80%), IL-10 (100%), and MHC-II (108%) and slightly up-regulated NKG2D (23%). However, in animals that received both L5178Y implantation and LPS, M were found to secrete significant amounts of IL-10 (218%), IFN-␥ (617%), and TNF-␣ (970%) and up-regulated CD86 (30.6%) and MHC-II (1088%), whereas expression of CD80 (8.7%) and secretion of IL-4 (14%) and IL-12 (13%) was almost unaltered. Although the level of NKG2D expression on mouse M from the L5178Y plus LPS group was 27% higher than on M from control pretreatment and L5178Y-only recipient groups (MFI ratio: 2.8 vs 2.2 vs 1.6), it was not different (3.7% increase) from the levels of expression on M from the LPS-only experimental group (MFI ratio: 2.8 vs 2.7).
In parallel (Fig. 11B) , we tested the in vivo antitumor effects of M primed to LPS by L178Y cells and found that proliferation of CFSE-labeled L5178Y cells injected i.p. was suppressed in DBA/2 mice after i.v. administration of a low amount of LPS. Thus, CFSE ϩ L5178Y cells unrestrictedly proliferated in control, PBStreated animals, and by the end of the experiment retained only 4.5% of CFSE fluorescence as compared with CFSE ϩ L5178Y cells that were kept in medium in vitro and were ␥-irradiated before incubation to permanently suppress their proliferation. At the same time, CFSE ϩ L5178Y from animals that were challenged with LPS 24 h after CFSE ϩ L5178Y implantation were found to retain ϳ20% of the amount of CFSE as compared with control, ␥-irradiated cells. Similar results were seen with CFSE ϩ L5178Y cells cultured with naive M in vitro. Together, these results show that L5178Y cells can prime naive M in vivo to subsequent stimulation with LPS, which results in M activation, as revealed by phenotypic alterations, change of cytokine expression, and antitumor activity.
Discussion
In this study, we demonstrate that M can recognize L5178Y tumor cells. Previous studies indicated that isolated ligation of CD40, NKG2D, and CD18 can be involved in activation of M (17, 20, 23) . Our current study dissects a functional hierarchy of these interactions in a polyvalent cross-talk between tumor cells and M. Even though CD154 is expressed in relatively low amounts on L1578Y cells (Fig. 5A) , its role in priming of M via CD40 was found to have a much greater stimulatory impact on M than M cross-linking via CD18 by ICAM-1 and ICAM-2, which are highly expressed on L5178Y cells. Similarly, whereas isolated blockage of NKG2D-H60 interactions had no noticeable effect on M in in vitro secretory and antitumor activities, it was required, in addition to blockage of CD40-CD154 and CD18-ICAM-1/2, for abrogation of M activation by L5178Y cells. Thus, the M-tumor cell cross-talk that ultimately leads to induction of antitumor M involves concurrent engagement of multiple receptor-ligand pairs.
It also appears that tumor cells should simultaneously express several stimulatory ligands to induce M activation. In this regard, normal syngeneic mouse splenocytes (essentially comprised of CD3 ϩ T cells (ϳ35%), B220 ϩ B cells (ϳ40%), CD11b ϩ mononuclear cells (ϳ10%), and CD49b ϩ NK cells (5-7%) did not prime M, in contrast to priming by L5178Y cells. Whereas most of the splenocytes expressed ICAM-1 and ICAM-2 (in a very heterogeneous fashion), only a small fraction (mostly CD4 ϩ T cells, Ͻ15% of total naive splenocytes) expressed CD154 (and only at very low levels), and no splenocytes expressed ligands of NKG2D (data not shown). Activation of splenocytes with LPS and CpG to produce IL-12 and IFN-␥ (24 -27) might facilitate M activation and induce moderate levels of antitumor effects in vitro without involvement of the CD40/NKG2D/CD18-dependent mechanism; however, in our in vitro experiments, splenocytes did not trigger NO production by M. Indeed, culturing M with 1 ϫ Several reports have previously demonstrated that the M. arginini-infected L5178Y and YAC-1 cell lines could activate thioglycolate-elicited peritoneal M in the presence of LPS or exogenous IFN-␥ to mediate in vitro antitumor effects via NO-and TNF-␣-dependent mechanisms (28, 29) . Results of those studies differed in the sensitivity of the model to the suppressive effects of PGE 2 , but both agreed that the priming effects could be transferred by the tumor cell-conditioned supernatants or mediated by paraformaldehyde-fixed tumor cells. In our study, we tested the L5178Y cell line for Mycoplasma spp. contamination and found no evidence for infection. The absence of Mycoplasma spp. in L5178Y cells was also confirmed at a DNA level by using fluorescent probes (data not shown). Most importantly, our results, unlike those published by Young et al. (28) and Ribeiro-Dias et al. (29) , suggest that priming of M required direct cell contact with viable L5178Y cells; M could not be primed by either L5178Y cell-conditioned supernatants (Fig. 5C) or fixed L5178Y cells. Furthermore, separation of M and viable L5178Y cells by the TW also abrogated priming of M. Whereas we cannot exclude a contribution of soluble, LPS-induced tumor cell-derived factors, such as IL-1 (30), our results suggest that membrane-bound, but not soluble factors are important for induction of cytotoxic M in our in vitro model. The inability of fixed L5178Y cells to prime M might also be due to potential toxic effects of fixed L5178Y cells on M (such as leaching of paraformaldehyde). However, our preliminary data argue against this, because coculture of fixed L5178Y cells with viable L5178Y cells did not affect proliferation of viable L5178Y cells as measured by [ 3 H]TdR incorporation (data not shown). The complete absence of M priming by fixed L5178Y cells in our in vitro experiments could be explained by denaturation of CD154 subunits by paraformaldehyde or by the inability of fixed L5178Y cells to up-regulate CD154 expression upon contact with M in the presence of LPS, which might be important for compensation of CD40 down-regulation on L5178Y-primed M. Lastly, loss of L5178Y cell membrane fluidity and inability of PF-L5178Y cells to mobilize CD154-, H60-or ICAM-1-and ICAM-2-containing membrane rafts to the site of direct contact with M might also lead to this loss of M-priming properties, provided that the cells express no other priming substances such as those associated with Mycoplasma spp. contamination (28, 29) .
Despite high concentrations of NO produced by the L5178Y cell plus LPS-stimulated M, L5178Y cell proliferation in the TW chamber was not suppressed when cocultured with L5178Y cell plus LPS-stimulated M in the bottom of the TW chamber system. In contrast, direct contact with M resulted in substantial antitumor effects, suggesting membrane-mediated death signaling. In this regard, we found only very limited expression of membranebound TNF-␣, FasL, and TRAIL on the surface of M after their exposure to L5178Y cells and LPS (data not shown). The potential roles of other factors in L5178Y plus LPS-stimulated M-mediated cytotoxicity remain to be clarified.
Flow cytometric analysis of the immunophenotype of M and L5178Y cells revealed that exposure of these cells to each other results in changes in expression of some of the Ags forming certain receptor-ligand pairs. Hence, a relative decrease (7-25%) of CD40 expression on M coincided with up-regulation (31-88%) of CD154 on L5178Y cells after these cells were cultured in the presence of LPS. Similarly, up-regulation (44 -127%) of NKG2D on M coincided with a slight decrease (11-16%) in expression of H60 on L5178Y cells. The observed alterations of the CD40-CD154 pair expression could favor recognition of L5178Y cells via CD154. The decreased expression of H60 on L5178Y cells following contact with M is in agreement with the observation by Bui et al. (31) that type I IFN down-regulated H60 in some tumors and could be associated with mechanisms of immune evasion (32); yet, we observed up-regulation of NKG2D expression on L5178Y lymphomaprimed M in the presence of LPS (Fig. 4) . Unlike the increased MHC-I we have noted on tumor cells escaping from NK cell effects (33) , there was no substantive change in MHC-I expression on L5178Y cells cultured with M (Fig. 5B) . Treatment of L5178Y cells with anti-MHC-I mAb did not alter secretory and antiproliferative functions of M (Fig. 7) . In agreement with this, we have recently demonstrated that anti-CD40-induced M-mediated in vivo antitumor effects can be effectively induced against both highly and weakly immunogenic tumors, independent of MHC-I expression (34) .
Although the expression of NKG2D and its potential role in M activation and M-mediated killing has been controversial (17, 35) , our data document up-regulation of cell surface NKG2D on M when cultured along with L5178Y cells and LPS. Furthermore, we demonstrate the abrogation of M activation in these cultures when M-based CD40, CD18, and NKG2D molecules are simultaneously prevented from recognizing their respective ligands. These data are consistent with the demonstration that mouse M activated by LPS and IFN-␥ up-regulate NKG2D and these activated M kill tumor cells that express adenovirus E1A in an NKG2D-dependent manner (J. Routes, manuscript in preparation). In a variety of immunological reactions, M can serve as APCs providing stimuli for T cells by MHC-II-associated exogenous Ags as well as via a number of costimulatory molecules. However, engagement of certain cell surface molecules on M causes reciprocal signaling, resulting in M activation. Several M membrane-associated surface molecules, including CD40, MHC-II, and CD18, could be involved in this reciprocal stimulation associated with modulation of signaling pathways, production of cytokines, and changes of immunophenotype. Frequently, ligation of more than one type of molecule on the surface of M is required for induction of cytokines. For example, it was shown that interaction of M with T cells via CD40-CD154 leads to accumulation of IL-12p40 in M; at the same time, additional contacts via the MHC-II-TCR pair was needed to trigger M to produce IL-12p35, thus enabling production of functional IL-12p70 (36 -38) . Our results demonstrate that L5178Y lymphoma cells express high amounts of H60 as well as ICAM-1 and ICAM-2. Thus, it is possible that H60 and ICAM-1/2 molecules could synergize with CD154 in M activation. The potential mechanisms of these additional interactions between M and L5178Y cells remain to be clarified, but could range from a simple anchoring of the ICAM ϩ tumor cells to the surface of CD18 ϩ M (18) (to facilitate cross-talk via CD40-CD154 and NKG2D-H60 pairs) to an active recruitment of a Toll/IL-1R family-like cascade to modulate TLR signaling (39) . The latter effect on adapter proteins of TLR signaling pathways might partially explain selective sensitivity of L5178Y-primed M to LPS but not CpG, although the most likely explanation is that peritoneal mouse M readily express TLR4 (40) , whereas TLR9 expression is negligible without proper stimulation (21) .
Alternatively, the ability to prime M may be restricted to the cells of a certain embryonic origin. Thus, L5178Y cells and A20 cells of lymphoid origin could prime M (for A20 cells, presence of the exogenous ␣CD40 (Fig. 8A ) or other CD40L-expressing cells (Fig. 10B ) was required), whereas B16 melanoma cells (neural crest origin) and mouse fibroblast L cells (mesenchymal origin) did not have this ability even in the presence of exogenous anti-CD40 (B16; Fig. 8A ) or after transfection with functional CD40L (CD40L-L; Fig. 9 ). L5178Y and A20 cells have also been able to facilitate priming by other CD154 ϩ cells (CD40L-L), but this costimulatory ability has been lost when cells were paraformaldehyde fixed (data not shown). Importantly, this effect was independent from the CD154-expressing status of these lymphoma cells, as A20 cells are CD154 negative (Fig. 5A ). Hence, it remains possible that some soluble factors or other surface costimulatory molecules expressed by lymphoid cells in the process of initial cross-talk between tumor cells and M, are involved in the process of M priming.
The conclusions made from in vitro experiments were consistent with data obtained in our in vivo tumor model. Intraperitoneal implantation of L5178Y cells resulted in alterations of the phenotype of resident M (up-regulation of MHC-II and down-regulation of CD80 and CD86), as well as expression of IFN-␥ and TNF-␣, but not IL-4 or IL-10 ( Fig. 11) . It is unclear whether these immunological changes are solely due to interaction of peritoneal M with L5178Y cells or whether this is a result of the cross-talk between M and tumor cells in the presence of very low, "physiological" concentrations of circulating endotoxin. However, when small doses of LPS were given to the tumor cell recipients, M expressed much higher levels of MHC-II, CD80, CD86, IFN-␥, and TNF-␣ than after the treatment with L5178Y cells or LPS alone. Surprisingly, there was a significant increase of production of IL-10, which is known to play an important role in regulation of M activation. The apparent discrepancy in the magnitude of M phenotypic changes seen in in vitro vs in vivo models may reflect differences in these experimental conditions. Thus, in in vitro experiments (Fig. 4) , M and L5178Y cells were in constant contact for the entire duration of the experiment, and the volume of distribution of M-derived and potentially L5178Y cell-derived soluble factors was confined to 0.2 ml. On the other hand, in the in vivo experiment, interactions between M and L5178Y cells could be less durable and the volume of distribution of soluble factors was much larger and potentially affected by physiologic metabolic processes. Even if the overall phenotypic changes are less pronounced in vivo, they are consistent with the in vitro data that demonstrate the principle that active M-L5178Y cell cross-talk results in phenotypic and functional alterations of M.
Efficient tumor recognition at the early stage of tumor progression might be a critical component of cancer immune surveillance. The state of "dormant" cancer exemplifies immune-mediated tumor growth restriction in the absence of active exogenous immunostimulatory interventions. L5178Y lymphoma in DBA/2 mice has been used for decades to study this biological phenomenon (41) (42) (43) (44) . Both CTLs and M are involved in maintaining L5178Y lymphoma in the dormant nonprogressive stage of disease (42) (43) (44) . In the present study, we suggest an additional mechanism of this immunological lymphoma surveillance: L5178Y cell-induced priming of M to endotoxin, which is naturally present in biological fluids in minute concentrations (45) , might be involved in M activation and result in antilymphoma effects in vivo. A number of reports demonstrate that human T cell lymphomas, as well as other cancers, can express CD154 (46 -51) . Whether human M can recognize autologous cancer cells via similar mechanisms, shown here for L5178Y cells, remains to be determined.
